SPRB
SPRUCE BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$40.40
+1.89%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -1.1%
- EBIT
- +5.6%
- EPS
- +53.2%
- Free cash flow
- +16.9%
- Operating cash flow
- +17.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +152.7%
- EPS
- +94.9%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +26.2%
- EBIT
- +35.0%
- Net income
- +26.5%
- EPS
- +47.5%
- Free cash flow
- +40.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026